What is Leerink Partnrs’ Forecast for MIRM Q3 Earnings?

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Research analysts at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for Mirum Pharmaceuticals in a report issued on Wednesday, February 26th. Leerink Partnrs analyst M. Foroohar anticipates that the company will post earnings per share of ($0.25) for the quarter. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.43) per share.

Several other research firms also recently weighed in on MIRM. HC Wainwright upped their price target on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Robert W. Baird boosted their target price on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an “outperform” rating in a report on Thursday, February 27th. Finally, Citigroup raised their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $58.20.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ MIRM opened at $45.22 on Monday. The company has a 50 day simple moving average of $47.11 and a two-hundred day simple moving average of $43.46. Mirum Pharmaceuticals has a fifty-two week low of $23.14 and a fifty-two week high of $54.23. The company has a market capitalization of $2.22 billion, a price-to-earnings ratio of -22.39 and a beta of 0.96. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business had revenue of $99.41 million during the quarter, compared to the consensus estimate of $96.64 million.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 750 shares of the business’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $32,115.00. Following the completion of the sale, the senior vice president now directly owns 2,926 shares in the company, valued at $125,291.32. The trade was a 20.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Christopher Peetz sold 7,489 shares of the stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $320,678.98. Following the completion of the transaction, the chief executive officer now owns 119,359 shares in the company, valued at $5,110,952.38. This trade represents a 5.90 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 40,915 shares of company stock valued at $1,897,920. 22.87% of the stock is owned by insiders.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. GF Fund Management CO. LTD. purchased a new position in shares of Mirum Pharmaceuticals during the 4th quarter valued at about $42,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Mirum Pharmaceuticals by 16.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 73,888 shares of the company’s stock worth $3,055,000 after acquiring an additional 10,427 shares during the period. Woodline Partners LP lifted its holdings in Mirum Pharmaceuticals by 22.2% during the fourth quarter. Woodline Partners LP now owns 404,404 shares of the company’s stock valued at $16,722,000 after purchasing an additional 73,399 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Mirum Pharmaceuticals in the fourth quarter worth approximately $897,000. Finally, Tema Etfs LLC purchased a new stake in shares of Mirum Pharmaceuticals in the fourth quarter worth $1,735,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.